Logan Capital Management Inc. Sells 1,594 Shares of Jazz Pharmaceuticals PLC $JAZZ

Logan Capital Management Inc. lessened its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 59.3% during the 2nd quarter, Holdings Channel.com reports. The firm owned 1,094 shares of the specialty pharmaceutical company’s stock after selling 1,594 shares during the period. Logan Capital Management Inc.’s holdings in Jazz Pharmaceuticals were worth $116,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in JAZZ. Hurley Capital LLC bought a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $25,000. Picton Mahoney Asset Management lifted its stake in shares of Jazz Pharmaceuticals by 2,445.5% in the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock worth $34,000 after purchasing an additional 269 shares during the period. Spire Wealth Management lifted its stake in shares of Jazz Pharmaceuticals by 137.6% in the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 161 shares during the period. SVB Wealth LLC bought a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $36,000. Finally, Geneos Wealth Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 137 shares during the period. Institutional investors own 89.14% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Morgan Stanley set a $183.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday. Wells Fargo & Company set a $170.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 22nd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a “buy” rating and a $152.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research note on Monday. Fourteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $179.33.

Jazz Pharmaceuticals Trading Down 0.9%

Jazz Pharmaceuticals stock opened at $138.13 on Wednesday. The stock has a market cap of $8.38 billion, a P/E ratio of -20.52, a PEG ratio of 8.89 and a beta of 0.28. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The firm’s 50 day moving average price is $131.25 and its 200-day moving average price is $117.51.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Bruce C. Cozadd sold 3,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $140.00, for a total transaction of $490,000.00. Following the sale, the director owned 408,826 shares in the company, valued at $57,235,640. This trade represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 11,500 shares of company stock worth $1,525,280 in the last quarter. Company insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.